Comparison of Risperidone and Haloperidol: Sleep Measures in Patients with Schizophrenia

比較服用Risperidone 與Haloperidol之精神分裂病人之睡眠差異

張鈺姍(Yu-San Chang) ； 陳泰瑞(Tai-Jui Chen) ； 陳明招(Ming-Chao Chen) ； 陳美月(Mei-Yueh Chen)

《台灣精神醫學》 22卷2期 (2008/06) Pp. 107-114

https://doi.org/10.29478/TJP.200806.0004

摘要

schizophrenia; polysomnography ;risperidone; Objective: The present study was undertaken to evaluate the relationship between objective and subjective sleep measures in patients with schizophrenia receiving risperidone relative to haloperidol-treated controls. Methods: In this cross-sectional observational study, sleep architecture and the Chinese version of Pittsburgh Sleep Quality Index (CPSQI) scores were compared for patients with schizophrenia receiving either risperidone (n=17) or haloperidol (n=18). All patients were diagnosed according to the relevant DSM-IV criteria, and clinical symptoms were evaluated by the Brief Psychiatric Rating Scale (BPRS). Polysomnography (PSG) was used to assess sleep architecture, and its correlation with the CPSQI was also investigated. Results: No differences were demonstrated comparing the two treatment groups in terms of their demographic characteristics, medication dosage, sleep architecture, or scores on the BPRS and the CPSQI and its sub-factors. Total and non-slow wave sleep times were negatively correlated with sleep latency (p＜0.05, p＜0.05), sleep disturbance (p＜0.05, p＜0.05) and global CPSQI scores (p＜0.05, p＜0.05) respectively, while positive correlation was demonstrated for subjective perception of extended sleep latency and objective measures of this prolongation (p＜0.01). Conclusions: The main pharmacological difference between risperidone and haloperidol is the more potent 5-HT2 receptor blockade provided by the former. Our lack of significant results indicates that further studies are needed to determine the mechanisms of 5-HT2 receptor antagonist involvement in sleep architecture. Sleep measures in our sample of patients with schizophrenia were consistent with objective and subjective findings in initial and maintenance sleep. Global subjective sleep quality assessment was associated with total sleep time. haloperidol

關鍵字

精神分裂病 ； 睡眠分析 ； risperidone ； Haloparidol

並列摘要

schizophrenia; polysomnography ;risperidone; Objective: The present study was undertaken to evaluate the relationship between objective and subjective sleep measures in patients with schizophrenia receiving risperidone relative to haloperidol-treated controls. Methods: In this cross-sectional observational study, sleep architecture and the Chinese version of Pittsburgh Sleep Quality Index (CPSQI) scores were compared for patients with schizophrenia receiving either risperidone (n=17) or haloperidol (n=18). All patients were diagnosed according to the relevant DSM-IV criteria, and clinical symptoms were evaluated by the Brief Psychiatric Rating Scale (BPRS). Polysomnography (PSG) was used to assess sleep architecture, and its correlation with the CPSQI was also investigated. Results: No differences were demonstrated comparing the two treatment groups in terms of their demographic characteristics, medication dosage, sleep architecture, or scores on the BPRS and the CPSQI and its sub-factors. Total and non-slow wave sleep times were negatively correlated with sleep latency (p＜0.05, p＜0.05), sleep disturbance (p＜0.05, p＜0.05) and global CPSQI scores (p＜0.05, p＜0.05) respectively, while positive correlation was demonstrated for subjective perception of extended sleep latency and objective measures of this prolongation (p＜0.01). Conclusions: The main pharmacological difference between risperidone and haloperidol is the more potent 5-HT2 receptor blockade provided by the former. Our lack of significant results indicates that further studies are needed to determine the mechanisms of 5-HT2 receptor antagonist involvement in sleep architecture. Sleep measures in our sample of patients with schizophrenia were consistent with objective and subjective findings in initial and maintenance sleep. Global subjective sleep quality assessment was associated with total sleep time. haloperidol

並列關鍵字

schizophrenia ； polysomnography ； risperidone ； haloperidol

參考文獻

Chouinard G,Jones B,Remington G(1993).A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidone in the treatment of chronic schizophrenic patients.J Clin Psychopharmacol.13,25-40.

Dursun SM,Patel JKM,Burke JG,Reveley MA(1999).Effects of typical antipsychotic drugs and risper-done on the quality of sleep in patients with schizophrenia: a pilot study.J Psychiatry Neurosci.24,333-337.

Haffmans PM,Oolders JM,Hoencamp E(2001).The effect of risperidone versus haloperidol on sleep patterns of schizophrenic patients: results of a double-blind, randomized pilot trial.Eur Neuro-psychopharm.11(3),260.

Yamashita H,Morinobu S,Yamawaki S,Horiguchi J,Nagao M(2002).Effects of risperidone on sleep in schizophrenia: a comparison with haloperidol.Psychiatry Res.109,137-142.

Yamashita H,Mori K,Nagao M,Okamoto Y,Morinobu S,Yamawaki S(2004).Effect of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population.J Clin Psychiatry.65,1525-1530.